Abstract
Atrial fibrillation (AF) is the most common cardiac arrhythmia. A subgroup of patients presents with AF without traditional risk factors and is diagnosed before the age of 60 years. Such patients are commonly referred as having “lone AF” and comprise 10-20% of all cases.
A number of studies have demonstrated that AF, and in particular lone AF, have a substantial genetic component. Genome-wide association studies (GWAS) have indicated that common single-nucleotide polymorphisms (SNPs) have a role in the development of AF. Furthermore, rare variants in genes encoding cardiac gap junction proteins, signalling molecules, ion channels, and accessory subunits have been associated with lone AF in several recent genetic reports. Most of these reports show gain-of-function or loss-of-function mutations, leading to increased risk of lone AF.
To date, the pathophysiological mechanisms responsible for AF are not fully understood, and it is likely that this arrhythmia represents a final common phenotype of multiple.
This review focuses on the genetic basis of lone AF and the role of both common and rare variants in the susceptibility of developing lone AF. Furthermore, three conceptual pathogenetic models of lone AF are discussed.
Keywords: Lone AF, GWAS, rare variants.
Current Pharmaceutical Design
Title:Genetic Aspects of Lone Atrial Fibrillation: What Do We Know?
Volume: 21 Issue: 5
Author(s): Laura Andreasen, Jonas B. Nielsen and Morten S. Olesen
Affiliation:
Keywords: Lone AF, GWAS, rare variants.
Abstract: Atrial fibrillation (AF) is the most common cardiac arrhythmia. A subgroup of patients presents with AF without traditional risk factors and is diagnosed before the age of 60 years. Such patients are commonly referred as having “lone AF” and comprise 10-20% of all cases.
A number of studies have demonstrated that AF, and in particular lone AF, have a substantial genetic component. Genome-wide association studies (GWAS) have indicated that common single-nucleotide polymorphisms (SNPs) have a role in the development of AF. Furthermore, rare variants in genes encoding cardiac gap junction proteins, signalling molecules, ion channels, and accessory subunits have been associated with lone AF in several recent genetic reports. Most of these reports show gain-of-function or loss-of-function mutations, leading to increased risk of lone AF.
To date, the pathophysiological mechanisms responsible for AF are not fully understood, and it is likely that this arrhythmia represents a final common phenotype of multiple.
This review focuses on the genetic basis of lone AF and the role of both common and rare variants in the susceptibility of developing lone AF. Furthermore, three conceptual pathogenetic models of lone AF are discussed.
Export Options
About this article
Cite this article as:
Andreasen Laura, Nielsen B. Jonas and Olesen S. Morten, Genetic Aspects of Lone Atrial Fibrillation: What Do We Know?, Current Pharmaceutical Design 2015; 21 (5) . https://dx.doi.org/10.2174/1381612820666140825143610
DOI https://dx.doi.org/10.2174/1381612820666140825143610 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacogenomic Considerations in the Treatment of the Pediatric Cardiomyopathy Called Barth Syndrome
Recent Patents on Biotechnology Antithrombotic Treatment after Atrial Fibrillation Ablation
Current Pharmaceutical Design The Antidiabetic Therapeutic Potential of Dietary Polyphenols
Current Pharmaceutical Biotechnology Beta-Blockers: Current State of Knowledge and Perspectives
Mini-Reviews in Medicinal Chemistry Neurodevelopmental Delay and Intellectual Disability in Pediatric Heart Transplant
Current Psychiatry Reviews Hypertension in Hemodialysis Patients
Current Hypertension Reviews Advanced Glycation End Products in Chinese Medicine Mediated Aging Diseases: A Review
Current Vascular Pharmacology Sepsis Pathophysiology and Anesthetic Consideration
Cardiovascular & Hematological Disorders-Drug Targets Trastuzumab-Induced Cardiotoxicity: Is it a Personalized Risk?
Current Drug Targets Myocardial Regeneration: What is the Best Approach?
Current Cardiology Reviews Methadone and the Heart: What the Clinician Needs to Know
Current Drug Abuse Reviews Hepatocyte Growth Factor and Insulin-like Growth Factor-1 based Cellular Therapies for Oxidative Stress Injury
Current Stem Cell Research & Therapy Therapeutic Interventions for Advanced Glycation-End Products and its Receptor- Mediated Cardiovascular Disease
Current Pharmaceutical Design The Effect of Acute Hypoxia on Excitability in the Heart and the L-Type Calcium Channel as a Therapeutic Target
Current Drug Discovery Technologies Editorial (Thematic Issue: Recent Advances in Management of Myocarditis)
Current Pharmaceutical Design Micro-RNA in Disease and Gene Therapy
Current Drug Discovery Technologies Stress, Cardiovascular Diseases and Surgery-Induced Angiogenesis
Current Angiogenesis (Discontinued) A Decrease in the Cellular Phosphodiester to Phosphomonoester Lipid Ratio is Characteristic of HIV-1 Infection
Current HIV Research Mesenchymal Stem Cell Therapy for Acetaminophen-related Liver Injury: A Systematic Review and Meta-analysis of Experimental Studies <i>In Vivo</i>
Current Stem Cell Research & Therapy Endothelial Dysfunction: Methods of Assessment and Application to Hypertension
Current Pharmaceutical Design